NEW YORK (GenomeWeb News) – Los Angeles-based firm Sidmap will collaborate with the Johns Hopkins School of Medicine in lung cancer metabolomics research using funding JHU was granted from the National Cancer Institute, the company said today.
The $340,000 grant will be used to test if a gain in function of a certain gene transcription factor called Nrf2 promotes tumorigenesis in the presence of a cancer-causing signal.
Sidmap conducts metabolomics research services for pharmaceutical and biotechnology partners in industry and to academic biomedical researchers.
Under the NCI grant, Sidmap's Chief Scientist Laszlo Boros and JHU School of Medicine Associate Professor Shyam Biswal will attempt to find out if a gain in Nrf2 function increases glucose metabolism through certain pathways that are essential to tumorigenesis. The research also will seek to discover if blocking an Nrf2-dependent pathway enzymes will inhibit the growth of non-small cell lung cancer cells and inhibit chemotherapy resistance.
The scientists will use Sidmap's metabolic profiling technology to help understand pathway regulation and to develop ways to target that pathway to circumvent resistance to chemotherapy.